{"favorite_id": 3929, "calc_type": "calculator", "dosing": false, "full_title_en": "Asymptomatic Myeloma Prognosis", "short_title_en": "Asymptomatic Myeloma Prognosis", "medium_description_en": "Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis.", "short_description_en": "Predicts risk of progression to active myeloma or amyloidosis.", "before_use": "", "instructions_en": "", "purpose_en": ["Prognosis"], "disease_en": ["Cancer", "Multiple Myeloma", "Hematologic Malignancy"], "specialty_en": ["Hematology and Oncology"], "chief_complaint_en": ["Extremity Pain", "Neck Pain", "Pain", "Weakness"], "system_en": ["Hematologic", "Oncologic"], "search_abbreviation_en": ["mm", "multiple myeloma", "myeloma", "smoldering myeloma", "asymptomatic myeloma", "prognosis"], "slug": "asymptomatic-myeloma-prognosis", "seo": {"meta_description_en": "The Asymptomatic Myeloma Prognosis predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis.", "keywords_en": "smm, smoldering myeloma"}, "content": {"how_to_use": {"use_case_en": "<p>Newly diagnosed multiple myeloma (MM) patients meeting International Myeloma Working Group criteria for smoldering or asymptomatic MM (see <a href=\"#pearls-pitfalls\">Pearls/Pitfalls</a> for criteria).</p>", "pearls_pitfalls_en": "<p>The Asymptomatic Myeloma Prognosis calculator classifies smoldering multiple myeloma (MM) patients into 3 prognostic groups, with differing risks of progression to active MM or amyloidosis.</p> <p>The criteria developed by the International Myeloma Working Group for diagnosis of smoldering multiple myeloma (SMM, or asymptomatic MM) are:</p> <ol> <li>Serum monoclonal protein \u22653 g/dL OR</li> <li>Plasma cells in bone marrow (BM) \u2265 10% AND</li> <li>No evidence of end-organ damage (no anemia, bone lesions, renal dysfunction, hypercalcemia, or recurrent bacterial infections)</li> </ol> <p>Prognosis and risk for progression to MM are quite variable.</p> <p>Overall progression risk was 10%/year for the first five years, 3%/yr for the next five years, then 1%/year for the next ten years. Cumulative risk for progression was 73% at 15 years.</p>", "why_use_en": "<ul> <li>Provides prognostic information for patients.</li> <li>Suggests patients who may need closer follow up.</li> <li>Allows for stratification of patients on clinical trials potentially evaluating newer, targeted myeloma therapies.</li> <li>Does not require FISH studies, cytogenetic, or MRI bone studies, which may add further discrimination but are not widely available; hence, generalizability is preserved in settings with limited availability of these studies.</li> </ul>"}, "next_steps": {"advice_en": "<p>Patients with smoldering or asymptomatic MM are currently observed. However, clinical trials should be sought for appropriate patients given the rapid progress in development of novel active agents.</p>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p><strong>High risk</strong></p>\n<ul>\n<li>BM plasmacytosis &ge;10% AND</li>\n<li>Serum monoclonal protein &ge;3 g/dL</li>\n</ul>\n<p><strong>Intermediate risk</strong></p>\n<ul>\n<li>BM plasmacytosis &ge;10% AND</li>\n<li>Serum monoclonal protein &lt;3 g/dL</li>\n</ul>\n<p><strong>Low risk</strong></p>\n<ul>\n<li>BM plasmacytosis &lt;10% AND</li>\n<li>Serum monoclonal protein &ge;3 g/dL</li>\n</ul>", "more_info_en": "<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td rowspan=\"2\">&nbsp;</td>\n<td colspan=\"3\">\n<p><strong>Risk of progression</strong></p>\n</td>\n<td rowspan=\"2\">\n<p><strong>Median time to progression</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>At 5 years</strong></p>\n</td>\n<td>\n<p><strong>At 10 years</strong></p>\n</td>\n<td>\n<p><strong>At 15 years</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>High risk</strong></p>\n</td>\n<td>\n<p>69%</p>\n</td>\n<td>\n<p>77%</p>\n</td>\n<td>\n<p>87%</p>\n</td>\n<td>\n<p>27 months (~2 years)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Intermediate risk</strong></p>\n</td>\n<td>\n<p>43%</p>\n</td>\n<td>\n<p>64%</p>\n</td>\n<td>\n<p>70%</p>\n</td>\n<td>\n<p>93 months (~8 years)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Low risk</strong></p>\n</td>\n<td>\n<p>15%</p>\n</td>\n<td>\n<p>33%</p>\n</td>\n<td>\n<p>39%</p>\n</td>\n<td>\n<p>228 months (~19 years)</p>\n</td>\n</tr>\n</tbody>\n</table>", "evidence_based_medicine_en": "<p>The Mayo Clinic analyzed 3,549 patients with myeloma referred between 1970 and 1995. 276 (8%) fulfilled criteria for smoldering multiple myeloma (SMM).</p> <p>Patients\u2019 bone marrows, labs and longitudinal records were reviewed. The end point was progression to active myeloma or amyloidosis requiring therapy.</p> <p><strong>Pertinent outcomes:</strong></p> <ol> <li>85% of SMM patients died, median follow up 11.6 years.</li> <li>57% developed active MM, with median survival after of 3.4 years.</li> <li>Cumulative probability of progression 51% at 5 years, 66% at 10 years, and 73% at 15 years.</li> <li>Risk of progression was 10% per year for the first 5 years, 3% per year for next 5 years, then 1% per year for the next 10 years.</li> </ol>", "references_list": {"Original/Primary Reference": [{"href": "http://www.ncbi.nlm.nih.gov/pubmed/17582068", "text": "Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007 Jun 21;356(25):2582-90. PMID:17582068."}], "Other References": [{"href": "", "text": ""}], "Validation": [{"href": "http://www.bloodjournal.org/content/126/23/4251", "text": "Kastritis E, Terpos E, et al. Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease. Blood 2015 126:4251"}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": [{"description": "<p>Randall (Randy) Pierce is in private practice with Northwest Georgia Oncology Centers in Carrollton, Georgia, where he has been in practice since 1998. After graduating from the University of Georgia in 1988, he attended medical school at the Medical College of Georgia. His internal medicine residency and hematology/oncology training were completed at Wake Forest University/Baptist Medical Center in 1998. Dr. Pierce treats most malignancies and has a special interest in myeloma and lymphoma. He is married, has 3 children, and enjoys playing tennis and deep sea fishing.</p>", "firstName": "Randall", "img": "randall-pierce.jpg", "lastName": "Pierce", "name": "Randall Pierce, MD", "target": "randall-pierce", "signedCOI": true, "hasDisclosure": []}]}, "reviewer": {"expert_name": []}, "creator": [{"name": "Dr. Robert A. Kyle", "creator_info": {"about_en": "<p>Robert A. Kyle, MD, is a professor of medicine and laboratory medicine and pathology at the Mayo Clinic in Rochester, Minnesota. He is widely regarded as a pioneer in multiple myeloma research, having published numerous critical papers on topics including monoclonal gammopathies, multiple myeloma, amyloidosis, and macroglobulinemia.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-robert-a-kyle.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=kyle+ra%5Bau%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "Bone marrow plasmacytosis", "name": "bmp", "options": [{"label": "\u226510%", "value": 0}, {"label": "<10%", "value": 1}], "conditionality": "", "show_points": false, "tips_en": "Average % from bone marrow aspirate and core biopsy", "optional": false}, {"type": "toggle", "label_en": "Serum monoclonal protein, g/dL", "name": "smp", "options": [{"label": "\u22653", "value": 0}, {"label": "<3", "value": 1}], "conditionality": "", "show_points": false, "tips_en": "On serum protein electrophoresis", "optional": false}], "md5": "af872cc4a57dbe567a21f374b36f71af", "cmeVersion": "3929.1", "related_calcs": [{"calcId": 3842, "short_title_en": "Revised Myeloma ISS", "slug": "revised-multiple-myeloma-international-staging-system-r-iss"}, {"calcId": 10232, "short_title_en": "Multiple Myeloma Response Criteria", "slug": "multiple-myeloma-response-criteria"}, {"calcId": 10233, "short_title_en": "Multiple Myeloma Diagnostic Criteria", "slug": "multiple-myeloma-diagnostic-criteria"}]}